ESC 365 - Influence of Atrial Fibrillation on Efficacy of Omecamtiv Mecarbil in Heart Failure: The GALACTIC-HF Trial

HFA Premium Access

Influence of Atrial Fibrillation on Efficacy of Omecamtiv Mecarbil in Heart Failure: The GALACTIC-HF Trial

Session: Late-Breaking Trials 1

Topic: Pharmacotherapy

Speaker: Professor S. Solomon (Boston, US)

Event: Heart Failure 2021

Congress Presentation

Add to my library

About the speaker

Professor Scott Solomon

Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)

73 presentations

28 followers

2 more presentations in this session

The effect of intravenous ferric-carboxymaltose on cardiac reverse remodeling following cardiac resynchronization therapy - The IRON CRT trial.

Speaker: Doctor P. Martens (Genk, BE)

Finerenone in patients with chronic kidney disease and type 2 diabetes, with and without a history of heart failure: a secondary analysis of the FIDELIO-DKD trial

Speaker: Professor G. Filippatos (Athens, GR)

Access the full session

Late-Breaking Trials 1

Speakers: Professor S. Solomon, Doctor P. Martens, Professor G. Filippatos

About the event

Heart Failure 2021

29 June - 1 July 2021

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources